Latest News and Press Releases

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME)Over 800 patients...

ZUG, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment ...

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing...

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule...

ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as...

ZUG, Sviss, March 11, 2025 (GLOBE NEWSWIRE) -- Árið 2024 var árangursríkt og einkenndist af verulegum áföngum þróunarlyfja Oculis á síðari stigum klínískra prófana fyrir meðferð á sjúkdómum í...

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting...

Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic...

ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...